The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, but its future within the broader market now triggers questions about long-term gains. Alternative versions are undercutting exclusivity , leading to concerns that investing in companies closely tied to Viagra's former influence could be a dangerous decision , es